恩替卡韦治疗中慢性乙型肝炎患者分泌白细胞介素22的T细胞频数变化研究  

The Study of Th1 and Th2 Cells During the Course of ETV Therapy in Chronic HBV Infection Patients

作　　者：宋春辉[1] 杨斌[1] 陈黎明[1] 石峰[1] 

机构地区：[1]解放军第302医院肝病生物治疗研究中心,北京100039

出　　处：《中国医药导刊》2011年第1期84-86,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:研究恩替卡韦(ETV)在慢性乙型肝炎治疗过程中患者外周血中分泌白细胞介素22(IL-22)的T细胞频数的变化。方法:在应用ETV治疗的不同时间点抽取HBV感染患者及健康对照者静脉血,分离血清及外周血单核细胞(PMBC),检测血清中乙型肝炎病毒表面标志物(HBV-M)、乙型肝炎病毒核酸定量(HBV-DNA)、丙氨酸转移酶(ALT)以及外周血中分泌IL-22的T细胞的频数。结果:应用ETV治疗后患者ALT及HBV-DNA从4周开始出现明显下降,IL-22+T细胞的频数相当于IL-22+IL-17+T细胞与IL-22+IL-17-T细胞的总数,在第4周时和基线点相比出现一个明显的升高,其后保持平稳,在36周时再次出现明显升高保持平稳至48周,在36周前低于健康对照,36周后明显高于健康对照。结论:ETV在有效抑制病毒复制的同时,IL-22+T细胞的作用和构成在HBV感染的过程中发生了变化,这种变化可能有利于肝脏炎症的减轻,但可能不利于病毒的清除。Objective：To invetigate the feature of IL-22＋T cells in chronically HBV-infected patients with enticarvir treatment.Methods： Serum and PBMCs were obtained from enrolled CHB patients and health controls and monitored for ALT, HBV DNA,HBV Markers as well as the frequency of IL-22＋T cells.Results：There was a significant decrease in ALT and HBV DNA levels in patients at 4th week since the ETV therapy, the frequency of IL-22＋T ceils increased significantly from 4th week and increased in 36th again, higher than controls from 36 week. Conclusion： ETV efficiently suppress HBV replication, the change of frquency and composition in IL-22＋ T ceils might attenuate hepatic inflammation but impaired clearing virus.

关 键 词：恩替卡韦 乙肝病毒 T细胞 白细胞介素22 

分 类 号：R512.62[医药卫生—内科学] R978.7[医药卫生—临床医学]